Minjie Gao1,2, Hua Bai1, Yogesh Jethava1, Yujie Wu3, Yuqi Zhu1, Ye Yang1, Jiliang Xia1, Huojun Cao4, Reinaldo Franqui-Machin1, Kalyan Nadiminti1, Gregory S Thomas1, Mohamed E Salama5, Peter Altevogt6, Gail Bishop7, Michael Tomasson1, Siegfried Janz8, Jumei Shi2, Lijuan Chen3, Ivana Frech1, Guido Tricot1, Fenghuang Zhan1. 1. Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA. 2. Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. 3. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. 4. Iowa Institute for Oral Health Research, College of Dentistry, The University of Iowa, Iowa City, IA. 5. Department of Pathology, University of Utah, and Associated Regional University Pathologists Laboratories, Salt Lake City, UT. 6. Skin Cancer Unit, German Cancer Research Center, and University Medical Center Mannheim, Germany. 7. Department of Microbiology and Immunology, University of Iowa and VA Medical Center, Iowa City, IA. 8. Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Abstract
BACKGROUND: Treatment failures in cancers, including multiple myeloma (MM), are most likely due to the persistence of a minor population of tumor-initiating cells (TICs), which are noncycling or slowly cycling and very drug resistant. METHODS: Gene expression profiling and real-time quantitative reverse transcription polymerase chain reaction were employed to define genes differentially expressed between the side-population cells, which contain the TICs, and the main population of MM cells derived from 11 MM patient samples. Self-renewal potential was analyzed by clonogenicity and drug resistance of CD24+ MM cells. Flow cytometry (n = 60) and immunofluorescence (n = 66) were applied on MM patient samples to determine CD24 expression. Therapeutic effects of CD24 antibodies were tested in xenograft MM mouse models containing three to six mice per group. RESULTS: CD24 was highly expressed in the side-population cells, and CD24+ MM cells exhibited high expression of induced pluripotent or embryonic stem cell genes. CD24+ MM cells showed increased clonogenicity, drug resistance, and tumorigenicity. Only 10 CD24+ MM cells were required to develop plasmacytomas in mice (n = three of five mice after 27 days). The frequency of CD24+ MM cells was highly variable in primary MM samples, but the average of CD24+ MM cells was 8.3% after chemotherapy and in complete-remission MM samples with persistent minimal residual disease compared with 1.0% CD24+ MM cells in newly diagnosed MM samples (n = 26). MM patients with a high initial percentage of CD24+ MM cells had inferior progression-free survival (hazard ratio [HR] = 3.81, 95% confidence interval [CI] = 5.66 to 18.34, P < .001) and overall survival (HR = 3.87, 95% CI = 16.61 to 34.39, P = .002). A CD24 antibody inhibited MM cell growth and prevented tumor progression in vivo. CONCLUSION: Our studies demonstrate that CD24+ MM cells maintain the TIC features of self-renewal and drug resistance and provide a target for myeloma therapy.
BACKGROUND: Treatment failures in cancers, including multiple myeloma (MM), are most likely due to the persistence of a minor population of tumor-initiating cells (TICs), which are noncycling or slowly cycling and very drug resistant. METHODS: Gene expression profiling and real-time quantitative reverse transcription polymerase chain reaction were employed to define genes differentially expressed between the side-population cells, which contain the TICs, and the main population of MM cells derived from 11 MM patient samples. Self-renewal potential was analyzed by clonogenicity and drug resistance of CD24+ MM cells. Flow cytometry (n = 60) and immunofluorescence (n = 66) were applied on MM patient samples to determine CD24 expression. Therapeutic effects of CD24 antibodies were tested in xenograft MM mouse models containing three to six mice per group. RESULTS:CD24 was highly expressed in the side-population cells, and CD24+ MM cells exhibited high expression of induced pluripotent or embryonic stem cell genes. CD24+ MM cells showed increased clonogenicity, drug resistance, and tumorigenicity. Only 10 CD24+ MM cells were required to develop plasmacytomas in mice (n = three of five mice after 27 days). The frequency of CD24+ MM cells was highly variable in primary MM samples, but the average of CD24+ MM cells was 8.3% after chemotherapy and in complete-remission MM samples with persistent minimal residual disease compared with 1.0% CD24+ MM cells in newly diagnosed MM samples (n = 26). MM patients with a high initial percentage of CD24+ MM cells had inferior progression-free survival (hazard ratio [HR] = 3.81, 95% confidence interval [CI] = 5.66 to 18.34, P < .001) and overall survival (HR = 3.87, 95% CI = 16.61 to 34.39, P = .002). A CD24 antibody inhibited MM cell growth and prevented tumor progression in vivo. CONCLUSION: Our studies demonstrate that CD24+ MM cells maintain the TIC features of self-renewal and drug resistance and provide a target for myeloma therapy.
Authors: Jianlong Wang; Sridhar Rao; Jianlin Chu; Xiaohua Shen; Dana N Levasseur; Thorold W Theunissen; Stuart H Orkin Journal: Nature Date: 2006-11-08 Impact factor: 49.962
Authors: Jonathan B Overdevest; Shibu Thomas; Glen Kristiansen; Donna E Hansel; Steven C Smith; Dan Theodorescu Journal: Cancer Res Date: 2011-04-11 Impact factor: 12.701
Authors: T Lapidot; C Sirard; J Vormoor; B Murdoch; T Hoang; J Caceres-Cortes; M Minden; B Paterson; M A Caligiuri; J E Dick Journal: Nature Date: 1994-02-17 Impact factor: 49.962
Authors: Kelly Boucher; Nancy Parquet; Raymond Widen; Kenneth Shain; Rachid Baz; Melissa Alsina; John Koomen; Claudio Anasetti; William Dalton; Lia E Perez Journal: Clin Cancer Res Date: 2012-09-17 Impact factor: 12.531
Authors: Teru Hideshima; Constantine Mitsiades; Giovanni Tonon; Paul G Richardson; Kenneth C Anderson Journal: Nat Rev Cancer Date: 2007-08 Impact factor: 60.716
Authors: A V Salnikov; N P Bretz; C Perne; J Hazin; S Keller; M Fogel; I Herr; T Schlange; G Moldenhauer; P Altevogt Journal: Br J Cancer Date: 2013-03-19 Impact factor: 7.640
Authors: Margaretha A Skowron; Teresa K Becker; Lukas Kurz; Sina Jostes; Felix Bremmer; Florian Fronhoffs; Kai Funke; Gamal A Wakileh; Melanie R Müller; Aaron Burmeister; Thomas Lenz; Anja Stefanski; Kai Stühler; Patrick Petzsch; Karl Köhrer; Peter Altevogt; Peter Albers; Glen Kristiansen; Hubert Schorle; Daniel Nettersheim Journal: Mol Oncol Date: 2021-08-02 Impact factor: 6.603